Nanobiotix (NBTX) to Release Earnings on Monday

Nanobiotix (NASDAQ:NBTX) is anticipated to announce its H1 2025 results before the market opens on Monday, September 22nd. Analysts expect the company to announce earnings of ($0.2930) per share and revenue of $3.7190 million for the quarter. Investors may review the information on the company’s upcoming H1 2025 earningreport for the latest details on the call scheduled for Thursday, September 25, 2025 at 11:40 AM ET.

Nanobiotix Stock Performance

NASDAQ:NBTX opened at $11.57 on Friday. Nanobiotix has a 52 week low of $2.76 and a 52 week high of $13.20. The stock’s 50-day moving average price is $7.97 and its 200-day moving average price is $5.31.

Analyst Ratings Changes

A number of equities research analysts have recently commented on NBTX shares. Leerink Partners set a $14.00 target price on Nanobiotix in a research report on Thursday. HC Wainwright restated a “buy” rating on shares of Nanobiotix in a research report on Friday. Two research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $11.00.

About Nanobiotix

Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.